Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Mitsukazu Kishida"'
Autor:
Shigeru Kohno, Koichi Izumikawa, Takahiro Takazono, Taiga Miyazaki, Minoru Yoshida, Katsuhiko Kamei, Kenji Ogawa, Shuichi Taniguchi, Koichi Akashi, Kazuhiro Tateda, Hiroshi Mukae, Yoshitsugu Miyazaki, Fumito Okada, Yoshinobu Kanda, Hiroshi Kakeya, Junko Suzuki, Shun-ichi Kimura, Mitsukazu Kishida, Miyuki Matsuda, Yoshihito Niki
Publikováno v:
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
Isavuconazole is a convenient triazole antifungal agent with a broad antifungal spectrum. A randomized, open-label study (ClinicalTrials.gov, NCT03471988) was conducted to evaluate the efficacy and safety of isavuconazole in Japanese patients with de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daa0b639e60e6b6877e6991c44db5c67
https://pubmed.ncbi.nlm.nih.gov/36307059
https://pubmed.ncbi.nlm.nih.gov/36307059
Autor:
Hiroshi Hagino, Masataka Shiraki, Toshitaka Nakamura, Chika Irie, Masako Ito, Hideki Yoshikawa, Toshitsugu Sugimoto, Masao Fukunaga, Hideaki Kishimoto, Mitsukazu Kishida, Tetsuo Nakano, Teruki Sone
Publikováno v:
Advances in Therapy
To clarify the additional efficacy and safety benefits of 24 months’ treatment with the once-weekly formulation of teriparatide, which is currently used for 72 weeks. This was a multicenter, open-label, single-arm study conducted in Japan. Subjects
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dcb31c1ae23a7d1c255087b7d81c10d
https://pubmed.ncbi.nlm.nih.gov/28631217
https://pubmed.ncbi.nlm.nih.gov/28631217